Convalescent Plasma
6
0
0
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
17%
1 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (6)
Efficacy and Safety of COVID-19 Convalescent Plasma
Convalescent Plasma Therapy for Hospitalized Patients With COVID-19
COVID-19 Infection in Patients Receiving Anti-CD20 Therapy
A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection
Clinical Efficacy of Early Administration of Convalescent Plasma Among COVID-19 Cases in Egypt
Statistical and Epidemiological Study Based on the Use of Convalescent Plasma for the Management of Patients With COVID-19